DOSING REGIMEN OF ANTI-TIGIT ANTIBODY FOR TREATMENT OF CANCER

The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Liga...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MAYAWALA, Kapil, CAI, Mingmei, LI, Tommy Ruosi, ZENG, Zhen, HEALY, Jane Anne, LALA, Mallika, CHARTASH, Elliot, PREDOIU, Raluca Andreia, WILLIAMS, Sybil
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody. La présente invention concerne des schémas posologiques d'un anticorps anti-TIGIT utiles pour le traitement du cancer. En particulier, l'invention concerne le schéma posologique dans une polythérapie qui comprend l'administration d'un anticorps d'une protéine de mort programmée 1 (PD-1) ou d'un ligand de mort programmée 1 (PD-L1) et d'un anticorps anti-TIGIT.